Users Coming Off Slimming Medications Put On Weight Four Times Faster Compared to Those on Conventional Diets

A recent study reveals that individuals who discontinue blockbuster weight-loss injections like semaglutide or tirzepatide tend to recover reduced body mass far faster than those who end conventional lifestyle regimens.

Findings released in a leading health publication points out that while overweight individuals frequently drop a large proportion of their body weight while using the jabs, the mass comes back at an estimated rate of 0.8 kg per month once they quit.

"People buying such drugs should be cognizant of the risk of quick rebound weight gain when the medication ends," cautioned researcher Dr. Susan Jebb.

This pace of regain implies a reversion to pre-treatment weight in about one and a half years.

Weighing Therapies

The analysis, which reviewed dozens of studies involving over 9,000 of patients, contrasted the results of these new drugs with conventional dieting.

Researchers note that individuals who lose weight through lifestyle changes alone typically have a less rapid weight regain—perhaps 0.1 kg a month—post-intervention.

The Reason for the Quick Rebound

Nutrition scientists suggest the way of the injections is key to understanding the heightened weight return.

GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness.

"Artificially providing the hormone concentrations far above than normal might result in the body to generate a reduced amount of its endogenous GLP-1, and may also diminish sensitivity to its actions," explained Dr. Adam Collins, a dietetics researcher.

"Discontinuation of this medication means hunger is uncontrolled, making excessive eating far more likely."

A Lifelong Issue?

The NHS recommend the injections for people with weight-linked health risks, alongside prescribed lifestyle changes.

A number of clinicians argue that, given the likelihood of weight regain, the therapy should be considered ongoing.

This opinion is supported by pharmaceutical companies, who note that the results "underscore the chronic nature of excess weight," similar to managing conditions like diabetes.

User Accounts

Individuals who have come off the medication report a sudden return of cravings.

"It felt as if something activating and you become ravenous," said a patient.

The struggle is exacerbated if patients have not adopted permanent lifestyle or habit modifications during treatment.

Widespread Interest

Figures show that millions of people in the UK have tried these injections in the past year, with demand remaining high.

• Adoption is greater among women than men.
• The middle-aged age group shows the greatest usage rates.
• A large proportion obtain the drugs through private prescriptions rather than the NHS.

Ultimately, clinicians caution that while these medications are powerful agents for weight loss, they are not a permanent cure and lasting health benefits relies on integrated behavioural management.